In the realm of bioprocessing, the integration of in-line monitoring and analytics is revolutionizing the industry, paving the way for advanced AI-linked sensors that could potentially enable model-based process controls. This shift towards unified platforms is crucial for overcoming the challenges faced in bioprocess monitoring and control, particularly in the development of complex biologics such as cell and gene therapy and mRNA products.
The current reliance on at-line monitoring, off-line analytics, and legacy control systems hinders real-time visibility into process conditions, leading to a reactive approach to data analysis. This limitation not only increases the risks of process deviations but also contributes to production delays. Thus, the industry is transitioning towards in-line and on-line analytics to support automation, enhance process control, and facilitate faster decision-making.
The adaptation to in-line sensors and analytics is driving the development of integrated platforms that combine sensing, analysis, and control functionalities. The ultimate goal is to streamline the next generation of monitors and controls, making them user-friendly and easily integrable into multi-vendor systems. This shift towards proactive process management necessitates the expansion of standardized communications protocols to ensure seamless interoperability among different equipment vendors.
A critical bottleneck in this evolution is the challenge posed by basic communications and connectivity issues, stemming from legacy systems and outdated protocols. Achieving seamless connectivity among equipment from diverse vendors is pivotal for avoiding rigid workflows, costly workarounds, and production slowdowns. Embracing open standards and vendor-agnostic platforms is essential to foster data-driven decision-making as a standard practice in the bioprocessing industry.
The convergence of technology innovation, regulatory evolution, and organizational readiness is paramount for driving the adoption of advanced monitoring, analytical, and control capabilities. The seamless integration of these capabilities between development and manufacturing sites, coupled with closer collaboration among analytics, automation, and process groups, is key to instilling confidence in the adoption of these transformative technologies.
In addressing the need for scalability in bioprocessing, there is a shift towards scaling out rather than scaling up, with a focus on automating multiple small bioreactors running in parallel. This shift presents challenges in terms of integrating data from various sources into a unified platform, thereby increasing the potential points of failure. The adoption of standardized communication protocols, such as the Open Platform Communication (OPC) standard, plays a crucial role in overcoming these integration challenges and enabling the implementation of best-of-breed solutions.
Developing robust yet flexible sensors suitable for manufacturing environments while accommodating the demands of early development stages is a significant challenge. The complexity of modern biotherapeutics further underscores the need for sensors that exhibit high sensitivity, anti-fouling performance, and adaptability to varying buffer conditions. Integration into diverse manufacturing platforms necessitates the development of sensor solutions that are adaptable, scalable, and digitally compatible, ensuring seamless implementation across different bioprocess systems.
The integration of AI into bioprocessing is unlocking the potential to maximize the value of complex data sets, enabling real-time insights into upstream processes that can inform downstream adjustments. Automation is poised to revolutionize sampling processes, transitioning from offline to online and inline sampling methods. The combination of robotics, mass spectrometry, machine learning, and AI is driving towards a fully automated sampling process within the next decade, enhancing efficiency and robustness in bioprocessing operations.
Looking ahead, the industry is poised for a future where model-based controls harmonize data from small-scale parallel systems, leveraging AI systems to optimize bioprocessing operations. Cloud computing solutions are playing a pivotal role in enabling real-time monitoring and data analysis, offering scientists peace of mind and facilitating remote process monitoring. The continued evolution towards model-based controls, ruggedized systems, simplified workflows, and regulatory compliance sets a promising trajectory for the future of bioprocessing.
Key Takeaways:
– The bioprocessing industry is undergoing a transformation towards unified platforms integrating in-line monitoring and analytics for enhanced process control.
– Standardized communication protocols such as the OPC standard are essential for seamless interoperability among diverse bioprocessing equipment.
– The adoption of AI, robotics, and cloud computing is revolutionizing sampling processes and enabling real-time insights to optimize bioprocessing operations.
– Model-based controls driven by AI systems are poised to harmonize data and streamline bioprocessing operations towards increased efficiency and robustness.
Tags: biopharma, gene therapy, regulatory, upstream, automation, scale up, downstream, process analytical technology, mass spectrometry, bioprocess
Read more on genengnews.com